http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 14:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Sept. 10, 2026</chron></span> /PRNewswire/ -- <span value="LSE:HIK" idsrc="xmltag.org" >Hikma Pharmaceuticals PLC</span> (<span>Hikma, Group</span>) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in <location value="LC/us" idsrc="xmltag.org" >the United States</location>, <location value="LR/eur" idsrc="xmltag.org" >Europe</location>, and the <location value="LC/gb" idsrc="xmltag.org" >UK</location>. <span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span> has also filed a submission for its epinephrine nasal spray in <location value="LC/ca" idsrc="xmltag.org" >Canada</location>, with plans to expand filings beyond these markets in due course. </p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Hikma+advances+its+epinephrine+nasal+spray+with+multi-market+regulatory+filings/27047807.html Thu, 10 Sep 2026 14:20:00 -0400 HKMPF HKMPY http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/Press+Releases/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465 http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>June 4, 2026</chron></span> /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary <span value="ACORN:1579578299" idsrc="xmltag.org" >Hikma Pharmaceuticals USA Inc.</span>, (<span value="ACORN:4088551084" idsrc="xmltag.org" >Hikma</span>) offered the following comments on today's unanimous decision by the <span>Supreme Court of the United States</span> effectively ending Amarin's patent infringement litigation against the company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1206817/Hikma_Primary_Coral_Logo.jpg?id=OA2669570" title="" http://www.streetinsider.com/PRNewswire/Hikma+comments+on+Supreme+Court+of+the+United+States%27+unanimous+decision+in+favour+of+Hikma/26606980.html Thu, 04 Jun 2026 17:39:00 -0400 A.13676244 A.15795782 A.40885510 HIK HIK HIK HKMPY O.01685572 O.20313690 O.38359659 O.45986465